Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 0.0 | 0.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2 | 2.34 |
NAV | ₹62.31 | ₹32.37 |
Fund Started | 18 Jun 2012 | 17 Jul 2013 |
Fund Size | ₹3221.37 Cr | ₹121.56 Cr |
Exit Load | Exit load of 1% if redeemed within 1 month. | Exit load of 1%, if redeemed within 90 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 21.25% | 26.44% |
3 Year | 10.20% | 10.69% |
5 Year | 14.78% | 13.13% |
1 Year
3 Year
5 Year
Equity | 98.27% | 0.00% |
Cash | 1.73% | 99.26% |
Equity
Cash
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
---|---|
MarketAxess Holdings Inc | 2.86% |
Altria Group Inc | 2.76% |
Bio-Rad Laboratories Inc A | 2.65% |
Gilead Sciences Inc. (USA) | 2.64% |
Corteva Inc. | 2.62% |
Bristol-Myers Squibb Co | 2.54% |
Kenvue Inc. | 2.53% |
International Flavors & Fragrances Inc | 2.50% |
Pfizer INC | 2.50% |
U.S. Bancorp | 2.45% |
Name | Ritesh Lunawat | Bharat Lahoti |
Start Date | 28 Dec 2020 | 18 Sep 2017 |
Name
Start Date
Description | The investment objective of ICICI Prudential US Bluechip Equity Fund is to provide long term capital appreciation to investors by primarily investing in equity and equity related securities of companies listed on recognized stock exchanges in the United States of America. The Scheme shall also invest in ADRs/GDRs issued by Indian and foreign companies. | The scheme seeks to provide long term capital growth by investing predominantly in JPMorgan Funds - US Value Fund, an equity fund which invests primarily in a value style based portfolio of US companies. |
Launch Date | 18 Jun 2012 | 17 Jul 2013 |
Description
Launch Date